Base de dados : MEDLINE
Pesquisa : HP6.023 [Categoria DeCS]
Referências encontradas : 15134 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 1514 ir para página                         

  1 / 15134 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28453689
[Au] Autor:Maisonneuve P; Amar S; Lowenfels AB
[Ad] Endereço:Division of Epidemiology and Biostatistics, European Institute of Oncology, Milan, Italy.
[Ti] Título:Periodontal disease, edentulism, and pancreatic cancer: a meta-analysis.
[So] Source:Ann Oncol;28(5):985-995, 2017 05 01.
[Is] ISSN:1569-8041
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:Background: Periodontal disease (PD), now our commonest infectious disorder leads to tooth loss, and has been linked to various systemic diseases, including various types of cancer. The aim of this study is to provide a systematic review and a meta-analysis of the relationship between PD, edentulism, and pancreatic cancer (PC). Patients and methods: From an initial review of 327 references we selected eight studies concerning periodontitis or edentulism with sufficient quantitative information to allow us to examine the risk of PC. We used relative risks (RRs), hazard ratios, or odds ratios to measure the association between periodontitis, edentulism, and PC. We employed random effects models to obtain summary risks, and we also provide measures of study differences and possible biases. Results: The summary RR for periodontitis and PC was 1.74 [95% confidence interval (CI) 1.41-2.15] and 1.54 for edentulism (95% CI 1.16-2.05). There was no evidence of heterogeneity for either variable, and no evidence of publication bias. The studies included reports from three continents, suggesting that the association is generalizable. Most of the studies were adjusted for variables thought to be associated with PC, such as gender, smoking, BMI, diabetes, and alcohol. Conclusions: Using meta-analysis, both periodontitis and edentulism appear to be associated with PC, even after adjusting for common risk factors. As yet, the mechanisms linking oral disease and PC are uncertain, but could be related to changes in the oral microbiome-an area of current research.
[Mh] Termos MeSH primário: Neoplasias Pancreáticas/etiologia
Doenças Periodontais/complicações
Perda de Dente/complicações
[Mh] Termos MeSH secundário: Animais
Causalidade
Seres Humanos
Neoplasias Pancreáticas/mortalidade
Doenças Periodontais/mortalidade
Modelos de Riscos Proporcionais
Fatores de Risco
Perda de Dente/mortalidade
[Pt] Tipo de publicação:JOURNAL ARTICLE; META-ANALYSIS; REVIEW
[Em] Mês de entrada:1803
[Cu] Atualização por classe:180308
[Lr] Data última revisão:
180308
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170429
[St] Status:MEDLINE
[do] DOI:10.1093/annonc/mdx019


  2 / 15134 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28471111
[Au] Autor:Hao SR; Geng SC; Fan LX; Chen JJ; Zhang Q; Li LJ
[Ad] Endereço:State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, the First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou 310003, China.
[Ti] Título:Intelligent diagnosis of jaundice with dynamic uncertain causality graph model.
[So] Source:J Zhejiang Univ Sci B;18(5):393-401, 2017 May.
[Is] ISSN:1862-1783
[Cp] País de publicação:China
[La] Idioma:eng
[Ab] Resumo:Jaundice is a common and complex clinical symptom potentially occurring in hepatology, general surgery, pediatrics, infectious diseases, gynecology, and obstetrics, and it is fairly difficult to distinguish the cause of jaundice in clinical practice, especially for general practitioners in less developed regions. With collaboration between physicians and artificial intelligence engineers, a comprehensive knowledge base relevant to jaundice was created based on demographic information, symptoms, physical signs, laboratory tests, imaging diagnosis, medical histories, and risk factors. Then a diagnostic modeling and reasoning system using the dynamic uncertain causality graph was proposed. A modularized modeling scheme was presented to reduce the complexity of model construction, providing multiple perspectives and arbitrary granularity for disease causality representations. A "chaining" inference algorithm and weighted logic operation mechanism were employed to guarantee the exactness and efficiency of diagnostic reasoning under situations of incomplete and uncertain information. Moreover, the causal interactions among diseases and symptoms intuitively demonstrated the reasoning process in a graphical manner. Verification was performed using 203 randomly pooled clinical cases, and the accuracy was 99.01% and 84.73%, respectively, with or without laboratory tests in the model. The solutions were more explicable and convincing than common methods such as Bayesian Networks, further increasing the objectivity of clinical decision-making. The promising results indicated that our model could be potentially used in intelligent diagnosis and help decrease public health expenditure.
[Mh] Termos MeSH primário: Algoritmos
Gráficos por Computador
Diagnóstico por Computador/métodos
Icterícia/diagnóstico
Aprendizado de Máquina
Modelos Estatísticos
[Mh] Termos MeSH secundário: Teorema de Bayes
Causalidade
Simulação por Computador
Sistemas de Apoio a Decisões Clínicas
Seres Humanos
Icterícia/epidemiologia
Prevalência
Reprodutibilidade dos Testes
Sensibilidade e Especificidade
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180226
[Lr] Data última revisão:
180226
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170505
[St] Status:MEDLINE
[do] DOI:10.1631/jzus.B1600273


  3 / 15134 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28464911
[Au] Autor:Duiverman ML; Maagh P; Magnet FS; Schmoor C; Arellano-Maric MP; Meissner A; Storre JH; Wijkstra PJ; Windisch W; Callegari J
[Ad] Endereço:Department of Pulmonary Diseases, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands. m.l.duiverman@umcg.nl.
[Ti] Título:Impact of High-Intensity-NIV on the heart in stable COPD: a randomised cross-over pilot study.
[So] Source:Respir Res;18(1):76, 2017 May 02.
[Is] ISSN:1465-993X
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Although high-intensity non-invasive ventilation has been shown to improve outcomes in stable COPD, it may adversely affect cardiac performance. Therefore, the aims of the present pilot study were to compare cardiac and pulmonary effects of 6 weeks of low-intensity non-invasive ventilation and 6 weeks of high-intensity non-invasive ventilation in stable COPD patients. METHODS: In a randomised crossover pilot feasibility study, the change in cardiac output after 6 weeks of each NIV mode compared to baseline was assessed with echocardiography in 14 severe stable COPD patients. Furthermore, CO during NIV, gas exchange, lung function, and health-related quality of life were investigated. RESULTS: Three patients dropped out: two deteriorated on low-intensity non-invasive ventilation, and one presented with decompensated heart failure while on high-intensity non-invasive ventilation. Eleven patients were included in the analysis. In general, cardiac output and NTproBNP did not change, although individual effects were noticed, depending on the pressures applied and/or the co-existence of heart failure. High-intensity non-invasive ventilation tended to be more effective in improving gas exchange, but both modes improved lung function and the health-related quality of life. CONCLUSIONS: Long-term non-invasive ventilation with adequate pressure to improve gas exchange and health-related quality of life did not have an overall adverse effect on cardiac performance. Nevertheless, in patients with pre-existing heart failure, the application of very high inspiratory pressures might reduce cardiac output. TRIAL REGISTRATION: The trial was registered in the Deutsches Register Klinischer Studien (DRKS-ID: DRKS00007977 ).
[Mh] Termos MeSH primário: Ventilação não Invasiva/efeitos adversos
Ventilação não Invasiva/métodos
Respiração com Pressão Positiva/métodos
Doença Pulmonar Obstrutiva Crônica/terapia
Qualidade de Vida
Disfunção Ventricular Esquerda/diagnóstico
Disfunção Ventricular Esquerda/etiologia
[Mh] Termos MeSH secundário: Idoso
Causalidade
Estudos Cross-Over
Estudos de Viabilidade
Feminino
Seres Humanos
Masculino
Meia-Idade
Projetos Piloto
Respiração com Pressão Positiva/efeitos adversos
Prevalência
Doença Pulmonar Obstrutiva Crônica/complicações
Doença Pulmonar Obstrutiva Crônica/diagnóstico
Fatores de Risco
Volume Sistólico
Resultado do Tratamento
[Pt] Tipo de publicação:JOURNAL ARTICLE; RANDOMIZED CONTROLLED TRIAL
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180226
[Lr] Data última revisão:
180226
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170504
[St] Status:MEDLINE
[do] DOI:10.1186/s12931-017-0542-9


  4 / 15134 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28460645
[Au] Autor:Vangala C; Lenihan CR; Montez-Rath ME; Nair SS; Navaneethan SD; Ramanathan V; Winkelmayer WC
[Ad] Endereço:Baylor College of Medicine, Section of Nephrology, One Baylor Plaza, BCM 620 - 11D32.5, Houston, TX, 77030, USA.
[Ti] Título:Statin use and hip fractures in U.S. kidney transplant recipients.
[So] Source:BMC Nephrol;18(1):145, 2017 May 01.
[Is] ISSN:1471-2369
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Basic and translational research supports beneficial effects of statins on bone metabolism. Clinical studies suggest that statin use may reduce the risk of hip fractures in the general population. Whether statin use is associated with hip fracture risk in kidney transplant recipients, a particularly high-risk group for this outcome, is unknown. METHODS: From the U.S. Renal Data System (2007-2011), we identified all hip fracture events recorded in Medicare billing claims of first-time kidney transplant recipients. We then matched all cases to an unlimited number of controls on age (±3 years), sex, race (black vs. non-black), and time since transplant. Cases and controls were required to have >1 year of Medicare Parts A + B + D coverage and be without a recorded history of hip fracture. We ascertained any statin use in the previous year and defined adherent statin use as those who had filled prescriptions for statins to cover >80% of days in that year (proportion of days covered, PDC). We ascertained several potential confounders (demographics, comorbidities, BMI, transplant-related factors) and applied conditional logistic regression with multiple imputation for missing data to estimate odds ratios (OR) and 95% confidence intervals (CI). RESULTS: We identified 231 hip fracture cases (mean age 51.8 years; 53% female; 11.3% black; 6.9 years from transplant, and 9.9 years from ESRD) and 15,575 matched controls. Any prior statin use was present in 64.1% of cases and 60.3% of controls with 37.2% of cases and 33.9% of controls being found adherent. Unadjusted conditional logistic regression showed an OR of 1.17 (0.89-1.54) for any statin use, and a fully-adjusted OR of 0.89 (0.67-1.19). Compared with statin non-users, the adjusted OR for patients with lesser adherence (PDC ≤80%) and those with greater adherence (PDC >80%) were 0.93 (0.66-1.31) and 0.87 (0.63-1.20), respectively. CONCLUSION: Statin use was not associated with hip fracture risk in first-time kidney transplant recipients.
[Mh] Termos MeSH primário: Efeitos Colaterais e Reações Adversas Relacionados a Medicamentos/epidemiologia
Fraturas do Quadril/epidemiologia
Fraturas do Quadril/prevenção & controle
Inibidores de Hidroximetilglutaril-CoA Redutases/uso terapêutico
Falência Renal Crônica/epidemiologia
Falência Renal Crônica/reabilitação
Transplante de Rim/utilização
[Mh] Termos MeSH secundário: Conservadores da Densidade Óssea/uso terapêutico
Causalidade
Comorbidade
Efeitos Colaterais e Reações Adversas Relacionados a Medicamentos/diagnóstico
Feminino
Fraturas do Quadril/diagnóstico
Seres Humanos
Incidência
Falência Renal Crônica/diagnóstico
Masculino
Meia-Idade
Estudos Retrospectivos
Fatores de Risco
Estados Unidos/epidemiologia
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Bone Density Conservation Agents); 0 (Hydroxymethylglutaryl-CoA Reductase Inhibitors)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180226
[Lr] Data última revisão:
180226
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170503
[St] Status:MEDLINE
[do] DOI:10.1186/s12882-017-0559-9


  5 / 15134 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28460637
[Au] Autor:Jain A; McDonald HI; Nitsch D; Tomlinson L; Thomas SL
[Ad] Endereço:Faculty of Epidemiology and Population Health, London School of Hygiene and Tropical Medicine, London, WC1E7HT, UK. Anu.jain@lshtm.ac.uk.
[Ti] Título:Risk factors for developing acute kidney injury in older people with diabetes and community-acquired pneumonia: a population-based UK cohort study.
[So] Source:BMC Nephrol;18(1):142, 2017 May 01.
[Is] ISSN:1471-2369
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Acute kidney injury (AKI) is being increasingly recognised in ageing populations. There are a paucity of data about AKI risk factors among older individuals with diabetes and infections, who are at particularly high risk of AKI. The objective of this study was to evaluate the risk factors for developing acute kidney injury (AKI) amongst older patients with diabetes and community-acquired pneumonia (CAP) in England, and whether the impact of underlying kidney function varied with age. METHODS: This was a population-based retrospective cohort study over 7 years (01/04/2004-31/3/2011) using electronic health records from the Clinical Practice Research Datalink linked to Hospital Episode Statistics. The study population comprised individuals with diabetes aged ≥65 years with CAP. Associations between demographic, lifestyle factors, co-morbidities and medications and development of AKI within 28 days of CAP were explored in a logistic regression model. RESULTS: Among 3471 patients with CAP and complete covariate data, 298 patients developed subsequent AKI. In multivariable analyses, factors found to be independently associated with AKI included: male sex (adjusted odds ratio, aOR: 1.56 95% confidence interval (CI): 1.20-2.04), hypertension (aOR1.36 95% CI 1.01-1.85), being prescribed either angiotensin-converting-enzyme inhibitors or angiotensin-II-receptor-blockers (aOR: 1.59 95% CI: 1.19-2.13), or insulin (aOR: 2.27 95% CI: 1.27-4.05), presence of proteinuria (aOR 1.27 95% CI 0.98-1.63), and low estimated glomerular filtration rate (eGFR). The odds of AKI were more graded amongst older participants aged ≥80 years compared to those of younger age: for eGFR of ≤29 mL/min/1.73m (vs 60 ml/min/1.73m ) aOR: 5.51 95% CI 3.28-9.27 and for eGFR 30-59 mL/min/1.73m 1.96 95% CI 1.30-2.96, whilst any eGFR < 60 ml/min/1.73m was associated with approximately 3-fold increase in the odds of AKI amongst younger individuals (p-value for interaction = 0.007). CONCLUSIONS: The identified risk factors should help primary care and hospital providers identify high risk patients in need of urgent management including more intensive monitoring, and prevention of AKI following pneumonia.
[Mh] Termos MeSH primário: Lesão Renal Aguda/epidemiologia
Infecções Comunitárias Adquiridas/epidemiologia
Complicações do Diabetes/epidemiologia
Pneumonia/epidemiologia
[Mh] Termos MeSH secundário: Lesão Renal Aguda/diagnóstico
Distribuição por Idade
Idoso
Idoso de 80 Anos ou mais
Causalidade
Estudos de Coortes
Infecções Comunitárias Adquiridas/diagnóstico
Comorbidade
Complicações do Diabetes/diagnóstico
Feminino
Seres Humanos
Incidência
Masculino
Pneumonia/diagnóstico por imagem
Estudos Retrospectivos
Distribuição por Sexo
Reino Unido/epidemiologia
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180226
[Lr] Data última revisão:
180226
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170503
[St] Status:MEDLINE
[do] DOI:10.1186/s12882-017-0566-x


  6 / 15134 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Registro de Ensaios Clínicos
Texto completo
[PMID]:28460629
[Au] Autor:Reith C; Staplin N; Herrington WG; Stevens W; Emberson J; Haynes R; Mafham M; Armitage J; Cass A; Craig JC; Jiang L; Pedersen T; Baigent C; Landray MJ; SHARP Collaborative Group
[Ad] Endereço:Nuffield Department of Population Health (NDPH), University of Oxford, Oxford, UK. christina.reith@ndph.ox.ac.uk.
[Ti] Título:Effect on non-vascular outcomes of lowering LDL cholesterol in patients with chronic kidney disease: results from the Study of Heart and Renal Protection.
[So] Source:BMC Nephrol;18(1):147, 2017 May 01.
[Is] ISSN:1471-2369
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Reducing LDL cholesterol (LDL-C) with statin-based therapy reduces the risk of major atherosclerotic events among patients with chronic kidney disease (CKD), with no evidence of an excess risk of cancer or death from any non-vascular cause. However, non-randomized data have suggested that statin therapy may have effects (both adverse and beneficial) on particular non-vascular conditions that do not cause death. METHODS: The Study of Heart and Renal Protection (SHARP) randomized patients with CKD to simvastatin 20 mg plus ezetimibe 10 mg (simvastatin/ezetimibe) daily versus matching placebo. Participants were followed up at least 6 monthly and all post-randomization serious adverse events (SAEs) were recorded. This supplementary analysis reports the effects of treatment on non-vascular SAEs, overall, by system of disease, by baseline characteristics, and by duration of follow-up. RESULTS: During a median of 4.9 years follow-up, similar numbers of participants in the two groups experienced at least one non-vascular SAE (3551 [76.4%] simvastatin/ezetimibe vs 3537 [76.6%] placebo; risk ratio [RR] 0.99, 95% confidence interval [CI] 0.95-1.04). There was no good evidence of any significant effect of simvastatin/ezetimibe on SAEs attributed to any particular nonvascular disease system (of 43 comparisons, only 3 yielded an uncorrected p value < 0.05, of which the smallest was p = 0.02). The relative risk of any nonvascular SAE did not vary significantly among particular prognostic subgroups or by duration of follow-up. CONCLUSIONS: In the SHARP trial, allocation to simvastatin/ezetimibe combination therapy was not associated with any significant non-vascular hazard. TRIALS REGISTRATION: SHARP was retrospectively registered after the first participant was enrolled in 2003 at ISRCTN (ISRCTN54137607 on 31 January 2005: http://www.isrctn.com/ISRCTN54137607) and ClinicalTrials.gov (NCT00125593 on 29 July 2005: https://clinicaltrials.gov/ct2/show/NCT00125593).
[Mh] Termos MeSH primário: LDL-Colesterol/sangue
Efeitos Colaterais e Reações Adversas Relacionados a Medicamentos/mortalidade
Inibidores de Hidroximetilglutaril-CoA Redutases/administração & dosagem
Hipercolesterolemia/mortalidade
Hipercolesterolemia/prevenção & controle
Insuficiência Renal Crônica/mortalidade
[Mh] Termos MeSH secundário: Adulto
Idoso
Idoso de 80 Anos ou mais
Anticolesterolemiantes/administração & dosagem
Causalidade
Comorbidade
Feminino
Seres Humanos
Hipercolesterolemia/sangue
Incidência
Internacionalidade
Masculino
Meia-Idade
Fatores de Risco
Taxa de Sobrevida
Resultado do Tratamento
[Pt] Tipo de publicação:JOURNAL ARTICLE; RANDOMIZED CONTROLLED TRIAL
[Nm] Nome de substância:
0 (Anticholesteremic Agents); 0 (Cholesterol, LDL); 0 (Hydroxymethylglutaryl-CoA Reductase Inhibitors)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180226
[Lr] Data última revisão:
180226
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170503
[Cl] Clinical Trial:ClinicalTrial
[St] Status:MEDLINE
[do] DOI:10.1186/s12882-017-0545-2


  7 / 15134 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29177261
[Au] Autor:Koutsikos J; Angelidis G; Zafeirakis A; Mamarelis I; Vogiatzis M; Ilia E; Lazaridis K; Demakopoulos N
[Ad] Endereço:Department of Nuclear Medicine Army Share Fund Hospital (417 NIMTS) Athens, Greece. jtkoutsik@yahoo.gr.
[Ti] Título:Performance and safety profile of regadenoson myocardial perfusion imaging: first experience in Greece.
[So] Source:Hell J Nucl Med;20(3):232-236, 2017 Sep-Dec.
[Is] ISSN:1790-5427
[Cp] País de publicação:Greece
[La] Idioma:eng
[Ab] Resumo:OBJECTIVE: MPI can provide valuable information in the investigation of patients with known or suspected coronary artery disease. The stress component of the studies can be conducted with regadenoson, which was approved for clinical use in Greece in 2016. We investigated the performance and safety profile of regadenoson MPI based on our 7 months institutional experience. PATIENTS AND METHODS: We studied 96 consecutive patients (59 males, 37 females, mean age 70.35y.o, range: 46-87y.o.) referred to our department for a clinically indicated MPI study with pharmacological stress. Eleven patients suffered from chronic obstructive pulmonary disease. Patients underwent regadenoson stress test, combined with both stress and rest imaging. Data on the symptoms and electrocardiographic changes due to regadenoson administration were recorded. Symptoms were graded as 1-mild: a symptom that did not distress the patient, 2-moderate: a symptom that distressed the patient but it was self-limiting, or 3-severe: a symptom that distressed the patient requiring medical intervention. RESULTS: Regadenoson-related symptoms were reported in 56 patients and were: dyspnea, discomfort, dizziness, chest pain, epigastric pain, neck pain, headache, flushing, nausea, heartburn, weakness, and upper limbs numbness. The severity of symptoms was recorded as grade 1 in 30 patients, grade 2 in 25 patients, and grade 3 in 1 patient. Two or more different symptoms were reported in 28 patients. Ischemic electrocardiographic changes and arrhythmias were observed in 8 patients. CONCLUSION: Our findings support previously published data indicating the optimal safety profile of regadenoson MPI, even in the group of patients suffering from chronic obstructive pulmonary disease.
[Mh] Termos MeSH primário: Doença da Artéria Coronariana/diagnóstico por imagem
Doença da Artéria Coronariana/epidemiologia
Efeitos Colaterais e Reações Adversas Relacionados a Medicamentos/epidemiologia
Teste de Esforço/estatística & dados numéricos
Imagem de Perfusão do Miocárdio/métodos
Purinas
Pirazóis
[Mh] Termos MeSH secundário: Idoso
Idoso de 80 Anos ou mais
Causalidade
Comorbidade
Efeitos Colaterais e Reações Adversas Relacionados a Medicamentos/diagnóstico
Feminino
Grécia/epidemiologia
Seres Humanos
Masculino
Meia-Idade
Imagem de Perfusão do Miocárdio/estatística & dados numéricos
Projetos Piloto
Tomografia por Emissão de Pósitrons/métodos
Tomografia por Emissão de Pósitrons/estatística & dados numéricos
Prevalência
Reprodutibilidade dos Testes
Fatores de Risco
Sensibilidade e Especificidade
Resultado do Tratamento
Vasodilatadores
[Pt] Tipo de publicação:CLINICAL TRIAL; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Purines); 0 (Pyrazoles); 0 (Vasodilator Agents); 2XLN4Y044H (regadenoson)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180223
[Lr] Data última revisão:
180223
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171128
[St] Status:MEDLINE
[do] DOI:10.1967/s002449910607


  8 / 15134 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:27776840
[Au] Autor:Lee JY; Ryu S; Cheong E; Sung KC
[Ad] Endereço:Division of Cardiology, Department of Medicine, Kangbuk Samsung Hospital, Sungkyunkwan University, School of Medicine, Seoul, Republic of Korea.
[Ti] Título:Association of Physical Activity and Inflammation With All-Cause, Cardiovascular-Related, and Cancer-Related Mortality.
[So] Source:Mayo Clin Proc;91(12):1706-1716, 2016 Dec.
[Is] ISSN:1942-5546
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:OBJECTIVE: To investigate the association between physical activity (PA) and risk of mortality in a large middle-aged cohort stratified by inflammatory status. PATIENTS AND METHODS: A total of 336,560 individuals (mean age, 39.7 years; 58% male) who underwent comprehensive health screenings were enrolled in this prospective cohort study. They were grouped according to self-reported PA level using a questionnaire: no regular PA with a sedentary lifestyle, regular but insufficient PA (below the guidelines), sufficient PA (concordant with the guidelines), and health-enhancing PA. Inflammation was assessed via high-sensitivity C-reactive protein (hsCRP) level. Study end points were all-cause, cardiovascular-related, and cancer-related mortality. RESULTS: During the 1,976,882 person-years of follow-up (median follow-up duration, 6.17 years), 2062 deaths occurred. Compared with a sedentary lifestyle, the hazard ratios (95% CIs) on the multivariable Cox proportional hazards regression analyses for all-cause mortality by PA level were 0.95 (0.84-1.07), 0.85 (0.72-0.99), and 0.75 (0.60-0.93) (P for trend=.003), and those for cardiovascular- and cancer-related mortality were 0.95, 0.80, and 0.55 (P for trend=.05) and 0.82, 0.83, and 0.78 (P for trend=.01), respectively. Compared with participants with low hsCRP levels and any regular PA, those with high hsCRP levels and no regular PA had a significantly higher risk of mortality (1.59 [1.38-1.84]). CONCLUSION: Higher PA levels were associated with a dose-dependent reduced risk of cardiovascular-related, cancer-related, and all-cause mortality. Individuals with high hsCRP levels and no regular PA had the highest risk of mortality.
[Mh] Termos MeSH primário: Doenças Cardiovasculares/mortalidade
Exercício/fisiologia
Mediadores da Inflamação/sangue
Inflamação/epidemiologia
Neoplasias/mortalidade
[Mh] Termos MeSH secundário: Adulto
Biomarcadores/sangue
Neoplasias da Mama/metabolismo
Proteína C-Reativa/metabolismo
Doenças Cardiovasculares/metabolismo
Causalidade
Estudos de Coortes
Comorbidade
Feminino
Seres Humanos
Inflamação/metabolismo
Masculino
Meia-Idade
Atividade Motora/fisiologia
Neoplasias/metabolismo
Estudos Prospectivos
Medição de Risco
Estados Unidos/epidemiologia
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Biomarkers); 0 (Inflammation Mediators); 9007-41-4 (C-Reactive Protein)
[Em] Mês de entrada:1705
[Cu] Atualização por classe:180222
[Lr] Data última revisão:
180222
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:161026
[St] Status:MEDLINE


  9 / 15134 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29370181
[Au] Autor:Lages J; Shepelyansky DL; Zinovyev A
[Ad] Endereço:Institut UTINAM, Observatoire des Sciences de l'Univers THETA, CNRS, Université de Franche-Comté, 25030 Besançon, France.
[Ti] Título:Inferring hidden causal relations between pathway members using reduced Google matrix of directed biological networks.
[So] Source:PLoS One;13(1):e0190812, 2018.
[Is] ISSN:1932-6203
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Signaling pathways represent parts of the global biological molecular network which connects them into a seamless whole through complex direct and indirect (hidden) crosstalk whose structure can change during development or in pathological conditions. We suggest a novel methodology, called Googlomics, for the structural analysis of directed biological networks using spectral analysis of their Google matrices, using parallels with quantum scattering theory, developed for nuclear and mesoscopic physics and quantum chaos. We introduce analytical "reduced Google matrix" method for the analysis of biological network structure. The method allows inferring hidden causal relations between the members of a signaling pathway or a functionally related group of genes. We investigate how the structure of hidden causal relations can be reprogrammed as a result of changes in the transcriptional network layer during cancerogenesis. The suggested Googlomics approach rigorously characterizes complex systemic changes in the wiring of large causal biological networks in a computationally efficient way.
[Mh] Termos MeSH primário: Redes Reguladoras de Genes
Modelos Biológicos
Ferramenta de Busca
Transdução de Sinais/genética
Transdução de Sinais/fisiologia
[Mh] Termos MeSH secundário: Algoritmos
Causalidade
Linhagem Celular
Biologia Computacional
Bases de Dados de Proteínas/estatística & dados numéricos
Seres Humanos
Células K562
Modelos Genéticos
Proteínas de Neoplasias/genética
Proteínas de Neoplasias/metabolismo
Neoplasias/genética
Neoplasias/metabolismo
Teoria Quântica
Processos Estocásticos
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Neoplasm Proteins)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180213
[Lr] Data última revisão:
180213
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:180126
[St] Status:MEDLINE
[do] DOI:10.1371/journal.pone.0190812


  10 / 15134 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29241889
[Au] Autor:Gyllensten H; Jönsson AK; Hakkarainen KM; Svensson S; Hägg S; Rehnberg C
[Ad] Endereço:Nordic School of Public Health NHV, Gothenburg, Sweden; Institute of Health and Care Sciences, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden; Division of Insurance Medicine, Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden. Electronic address: hanna.g
[Ti] Título:Comparing Methods for Estimating Direct Costs of Adverse Drug Events.
[So] Source:Value Health;20(10):1299-1310, 2017 12.
[Is] ISSN:1524-4733
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:OBJECTIVES: To estimate how direct health care costs resulting from adverse drug events (ADEs) and cost distribution are affected by methodological decisions regarding identification of ADEs, assigning relevant resource use to ADEs, and estimating costs for the assigned resources. METHODS: ADEs were identified from medical records and diagnostic codes for a random sample of 4970 Swedish adults during a 3-month study period in 2008 and were assessed for causality. Results were compared for five cost evaluation methods, including different methods for identifying ADEs, assigning resource use to ADEs, and for estimating costs for the assigned resources (resource use method, proportion of registered cost method, unit cost method, diagnostic code method, and main diagnosis method). Different levels of causality for ADEs and ADEs' contribution to health care resource use were considered. RESULTS: Using the five methods, the maximum estimated overall direct health care costs resulting from ADEs ranged from Sk10,000 (Sk = Swedish krona; ~€1,500 in 2016 values) using the diagnostic code method to more than Sk3,000,000 (~€414,000) using the unit cost method in our study population. The most conservative definitions for ADEs' contribution to health care resource use and the causality of ADEs resulted in average costs per patient ranging from Sk0 using the diagnostic code method to Sk4066 (~€500) using the unit cost method. CONCLUSIONS: The estimated costs resulting from ADEs varied considerably depending on the methodological choices. The results indicate that costs for ADEs need to be identified through medical record review and by using detailed unit cost data.
[Mh] Termos MeSH primário: Codificação Clínica/métodos
Custos e Análise de Custo/métodos
Efeitos Colaterais e Reações Adversas Relacionados a Medicamentos/economia
Custos de Cuidados de Saúde/estatística & dados numéricos
[Mh] Termos MeSH secundário: Adolescente
Adulto
Idoso
Causalidade
Efeitos Colaterais e Reações Adversas Relacionados a Medicamentos/diagnóstico
Feminino
Seres Humanos
Masculino
Registros Médicos/estatística & dados numéricos
Meia-Idade
Suécia
Adulto Jovem
[Pt] Tipo de publicação:COMPARATIVE STUDY; JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Em] Mês de entrada:1712
[Cu] Atualização por classe:180202
[Lr] Data última revisão:
180202
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171216
[St] Status:MEDLINE



página 1 de 1514 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde